Department of Medicine, Hamamatsu Oncology Center, 3-6-13 Chuo, Naka-ku, Hamamatsu, Shizuoka, 430-0929, Japan,
Breast Cancer. 2013 Oct;20(4):302-9. doi: 10.1007/s12282-013-0451-9. Epub 2013 Mar 1.
Oral fluoropyrimidine anticancer agents (oral 5-fluorouracil [5-FU]) able to be used as chemotherapy for breast cancer include tegafur-uracil (UFT), tegafur-gimeracil-oteracil potassium (S-1), doxifluridine, and capecitabine. Since the 1980s, UFT has been most widely used for postoperative chemotherapy in breast cancer. UFT is an oral preparation that was designed to achieve and maintain high concentrations of 5-FU in plasma by combining tegafur, a prodrug of 5-FU, with uracil. UFT is characterized by mild adverse events, allowing long-term treatment. The prolonged maintenance of high plasma 5-FU concentrations has been suggested to inhibit micrometastases after surgery. Recently, large clinical trials conducted in Japan have shown that UFT-based postoperative chemotherapy is therapeutically useful in patients with node-negative (n0), high-risk breast cancer. We review the results of clinical trials of postoperative chemotherapy with UFT in Japan and discuss its roles and future prospects.
可用于乳腺癌化疗的口服氟嘧啶类抗癌药（口服 5-氟尿嘧啶[5-FU]）包括替加氟-尿嘧啶（UFT）、替加氟-吉美嘧啶-奥替拉西钾（S-1）、多西氟尿嘧啶和卡培他滨。自 20 世纪 80 年代以来，UFT 已广泛用于乳腺癌术后化疗。UFT 是一种口服制剂，通过将 5-FU 的前体药物替加氟与尿嘧啶结合，旨在实现并维持血浆中 5-FU 的高浓度。UFT 的特点是不良反应较轻，允许长期治疗。长时间维持高血浆 5-FU 浓度被认为可以抑制手术后的微转移。最近，日本进行的大型临床试验表明，UFT 为基础的术后化疗对淋巴结阴性（n0）、高危乳腺癌患者具有治疗作用。我们回顾了日本 UFT 术后化疗的临床试验结果，并讨论了其作用和未来前景。
